PRINCETON, N.J.--(BUSINESS WIRE)--Mar 22, 2012-- Derma Sciences, Inc.

(Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on March 29, 2012 to discuss the financial results for the fourth quarter and year ended December 31, 2011. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern Daylight Time). The results will be released before the opening of the market that same day.

To access the conference call, U.S.-based listeners should dial 888-563-6275 and international listeners should dial 706-634-7417. All listeners should provide the following passcode: 62828362.

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast.

Following the end of the conference call, a replay will be available through April 4, 2012 and can be accessed by dialing (855) 859-2056 within the U.S. or (404) 537-3406 outside of the U.S. All listeners should provide the following passcode: 62828362. The webcast will also be available for 30 days.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings.

Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials.

Its MEDIHONEY(R) product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB(R) for better management of wound exudate, and BIOGUARD(R) for infection prevention.

For more information please visit

CONTACT: Derma Sciences, Inc.

John Yetter, 609-514-4744 Chief Financial Officer or LHA, Inc.

Investors: Kim Sutton Golodetz, 212-838-3777 or Bruce Voss, 310-691-7100 or Media: Mackenzie Mills, 212-838-3777 KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES PHARMACEUTICAL OTHER HEALTH MEDICAL SUPPLIES SOURCE: Derma Sciences, Inc.

Copyright Business Wire 2012 PUB: 03/22/2012 10:00 /DISC: 03/22/2012 10:00